SINGLE CENTRE EXPERIENCE WITH LONG-TERM FOLLOW-UP OF RECOMBINANT FACTOR VIIA IN PATIENTS UNDERGOING CARDIAC SURGERY

摘要

BACKGROUND: Peri-operative haemorrhage requiring massive transfusion represents a major challenge in cardiac surgery and is associated with significant morbidity and mortality. Re-combinant Factor Vila (rFVIIa) administration remains a controversial rescue therapy for intractable non-surgical bleeding. Variability in reported complications by small retrospective studies has led to a disparity in recommendations found in the literature.